A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).

Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B

Diabetes, obesity & metabolism11 Feb 2014Cited by 121 (Europe PMC)

PMID24443830DOI10.1111/dom.12262PepBankPUB-24443830

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin degludec and metformin, adding liraglutide reduced HbA1c more (-0.74%-points) than adding insulin aspart (-0.39%-points).
In plain wordsIn adults with type 2 diabetes on basal insulin, adding liraglutide lowered HbA1c more than adding mealtime insulin aspart.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at 26 weeks
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.74 %-points
IDeg+Lira
HbA1c change
−0.39 %-points
IDeg+IAsp
Estimated treatment difference
−0.32 %-points
95% CI -0.53; -0.12
Source sentences
Summary
IDeg+Lira reduced HbA1c (-0.74%-points) significantly more than IDeg+IAsp (-0.39%-points); estimated treatment difference (ETD) (IDeg+Lira-IDeg+IAsp) -0.32%-points (95% CI -0.53; -0.12); p = 0.0024.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383001
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin degludec and metformin, more patients reached HbA1c below 7.0% without confirmed hypoglycaemia and without weight gain with added liraglutide (49.4%) than with added insulin aspart (7.2%).
In plain wordsIn adults with type 2 diabetes on basal insulin, more people reached the HbA1c target safely with added liraglutide than with added insulin aspart.
Peptide
Liraglutide
Outcome
IncreaseHbA1c below 7.0% without confirmed hypoglycaemia and without weight gain
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Responders
49.4%
IDeg+Lira
Responders
7.2%
IDeg+IAsp
Estimated odds ratio
13.79
95% CI 5.24; 36.28
Source sentences
Summary
More IDeg+Lira (49.4%) than IDeg+IAsp (7.2%) subjects achieved HbA1c <7.0% without confirmed hypoglycaemia [plasma glucose <3.1 mmol/l (<56 mg/dl) or severe hypoglycaemia) and without weight gain; estimated odds ratio (IDeg+Lira/IDeg+IAsp) 13.79 (95% CI 5.24; 36.28); p < 0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383002
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin degludec and metformin, adding liraglutide gave significantly less confirmed hypoglycaemia than adding insulin aspart.
In plain wordsIn adults with type 2 diabetes on basal insulin, adding liraglutide led to fewer confirmed low blood sugar episodes than adding insulin aspart.
Peptide
Liraglutide
Outcome
DecreaseConfirmed hypoglycaemia
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
IDeg+Lira subjects had significantly less confirmed and nocturnal confirmed hypoglycaemia, and significantly greater weight loss (-2.8 kg) versus IDeg+IAsp (+0.9 kg); ETD (IDeg+Lira-IDeg+IAsp) -3.75 kg (95% CI -4.70; -2.79); p < 0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383003
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin degludec and metformin, adding liraglutide gave significantly less nocturnal confirmed hypoglycaemia than adding insulin aspart.
In plain wordsIn adults with type 2 diabetes on basal insulin, adding liraglutide led to fewer night-time confirmed low blood sugar episodes than adding insulin aspart.
Peptide
Liraglutide
Outcome
DecreaseNocturnal confirmed hypoglycaemia
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
IDeg+Lira subjects had significantly less confirmed and nocturnal confirmed hypoglycaemia
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383004
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin degludec and metformin, adding liraglutide gave weight loss (-2.8 kg) versus weight gain (+0.9 kg) with added insulin aspart.
In plain wordsIn adults with type 2 diabetes on basal insulin, adding liraglutide led to weight loss, whereas adding insulin aspart led to weight gain.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Weight change
−2.8 kg
IDeg+Lira
Weight change
0.9 kg
IDeg+IAsp
Estimated treatment difference
−3.75 kg
95% CI -4.70; -2.79
Source sentences
Summary
and significantly greater weight loss (-2.8 kg) versus IDeg+IAsp (+0.9 kg); ETD (IDeg+Lira-IDeg+IAsp) -3.75 kg (95% CI -4.70; -2.79); p < 0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383005
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin degludec and metformin, adding liraglutide caused more gastrointestinal side effects than adding insulin aspart.
In plain wordsIn adults with type 2 diabetes on basal insulin, adding liraglutide caused more stomach and bowel side effects than adding insulin aspart.
Peptide
Liraglutide
Outcome
IncreaseGastrointestinal side effects
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Other than more gastrointestinal side effects with IDeg+Lira
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383006
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin degludec and metformin, apart from gastrointestinal side effects, no safety differences occurred between added liraglutide and added insulin aspart.
In plain wordsIn adults with type 2 diabetes on basal insulin, apart from stomach and bowel side effects, safety did not differ between liraglutide and insulin aspart.
Peptide
Liraglutide
Outcome
No significant changeOther safety differences
Study
n: not reported in source
Comparator
Insulin aspart added to insulin degludec
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Other than more gastrointestinal side effects with IDeg+Lira, no safety differences occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c ≥ 7.0% (≥53 mmol/mol) were randomized to IDeg+Lira [n = 88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n = 89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin.
Report a problemFND-2444383007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01388361

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Novo Nordisk A/Sn = 413Sept 2011 to Jul 2012

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 6 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.